Anacor Pharmaceuticals Announces Third Quarter 2012 Financial Results Conference Call and Webcast
PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (ANAC) will release its financial results for the quarter ended September 30, 2012, on Wednesday, November 7, 2012 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the companys financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call and providing the conference ID 59069244. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the companys website at www.anacor.com and will be available for three months following the call.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered seven compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds - tavaborole, a topical antifungal for the treatment of onychomycosis and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively and AN3365 (formerly known as GSK2251052, or GSK 052) a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria which previously was licensed to GlaxoSmithKline LLC, or GSK. We have discovered two other compounds that we have out-licensed for further development AN8194, a compound for the treatment of an animal health indication that is licensed to Eli Lilly and Company, or Lilly, and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
Source: Anacor PharmaceuticalsCopyright Business Wire 2012